The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction

Catheterization and Cardiovascular Interventions

Volumn 89, Issue 2, 2017, Pages 169-177

  Henry, Timothy D ^a   Pepine, Carl J ^b   Lambert, Charles R ^c   Traverse, Jay H ^d   Schatz, Richard ^e   Costa, Marco ^f   Povsic, Thomas J ^g   David Anderson, R ^b   Willerson, James T ⁱ   Kesten, Steven ^h   Perin, Emerson C ⁱ  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Kiran C Patel Research Institute   (United States)

^d MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^e SCRIPPS GREEN HOSPITAL   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h Cytori Therapeutics Inc   (United States)

ⁱ TEXAS HEART INSTITUTE   (United States)

Author keywords

cardiomyopathy; heart failure; stem cell regenerative therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADIPOSE DERIVED STEM CELL; ADULT; AGED; ARTICLE; AUTOLOGOUS ADIPOSE DERIVED REGENERATIVE CELL; AUTOTRANSPLANTATION; BIOMEDICAL MICROELECTROMECHANICAL SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEASIBILITY STUDY; FEMALE; HEALTH PROGRAM; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HOSPITALIZATION; HUMAN; MALE; NEW YORK HEART ASSOCIATION CLASS; OXYGEN CONSUMPTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFRACTORY CHRONIC MYOCARDIAL ISCHEMIA; REVASCULARIZATION; SHORT FORM 36; SYSTOLIC BLOOD PRESSURE; ADIPOSE TISSUE; ADVERSE EFFECTS; CARDIAC MUSCLE; CHRONIC DISEASE; CLINICAL TRIAL; CONVALESCENCE; CYTOLOGY; DIAGNOSTIC IMAGING; DISEASE COURSE; EARLY TERMINATION OF CLINICAL TRIAL; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HOSPITAL READMISSION; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATION; STEM CELL TRANSPLANTATION; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADIPOSE TISSUE; AGED; CHRONIC DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; FEASIBILITY STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PATIENT READMISSION; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; REGENERATION; STEM CELL TRANSPLANTATION; STROKE VOLUME; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84994381343     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26601     Document Type: Article

References (23)

1. Henry TD, Satran D, Jolicoeur EM. Treatment of refractory angina in patients not suitable for revascularization. Nat Rev Cardiol 2014;11:78–95. PMID: 24366073
2. Jolicoeur EM, Ohman EM, Temple R, Stockbridge N, Smith S, Mark D, Califf RM, Henry TD, Chaitman BR, Granger CB, Working Group Members. Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. Am Heart J 2008;155:435–444.
3. Jolicoeur EM, Cartier R, Henry TD, Barsness GW, Bourassa MG, McGillion M, L'Allier PL. Patients with coronary artery disease unsuitable for revascularization: Definition, general principles, and a classification. Can J Cardiol 2012;28:S50–S59.
4. Henry TD, Satran D, Hodges JS, Johnson RK, Poulose AK, Campbell AR, Garberich RF, Bart BA, Olson RE, Boisjolie CR, Harvey KL, Arndt TL, Traverse JH. Long-term survival in patients with refractory angina. Eur Heart J 2013;34:2683–2688.
5. Fraser JK, Schreiber R, Strem B, Zhu M, Alfonso Z, Wulur I, Hedrick MH. Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes. Nat Clin Pract Cardiovasc Med 2006;3Suppl1:S33–S37.
6. Sanganalmath SK, Bolli R. Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013;113:810–834.
7. Perin EC, Willerson JT, Pepine CJ, Henry TD, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cell on functional capacity, left ventricular function, and perfusion in chronic heart failure-The FOCUS-CCTRN Trial. JAMA 2012;307:1717–1726.
8. Fisher S, Dorre C, Brunskill SJ, Mathur A, Martin-Rendon E. Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: A systematic review and meta-analysis. PLoS One 2013;9:e64669
9. Kandala J, Upadhyay GA, Pokushalov E, Wu S, Drachman DE, Singh JP. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol 2013;112:217–225.
10. Li N, Yang Y-J, Zhang Q, Jin C, Wang H, Qian H-Y. Stem cell therapy is a promising tool for refractory angina: A meta-analysis of randomized controlled trials. Can J Cardiol 2013;29:908–914.
11. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res 2015;116:1361–1377.
12. Khan AR, Farid TA, Pathan A, Tripathi A, Ghafghazi S, Wysoczynski M, Bolli R. Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: A systematic review and meta-analysis. Circ Res 2016;118:984–993.
13. Perin EC, Sanz-Ruiz R, Sánchez PL, Lasso J, Pérez-Cano R, Alonso-Farto JC, Pérez-David E, Fernández-Santos ME, Serruys PW, Duckers HJ, Kastrup J, Chamuleau S, Zheng Y, Silva GV, Willerson JT, Fernández-Avilés F. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J 2014;168:88–95.e2.
14. Planat-Benard V, Silvestre JS, Cousin B, André M, Nibbelink M, Tamarat R, Clergue M, Manneville C, Saillan-Barreau C, Duriez M, Tedgui A, Levy B, Pénicaud L, Casteilla L. Plasticity of human adipose lineage cells toward endothelial cells: Physiological and therapeutic perspectives. Circulation 2004;109:656–663.
15. Choi YS, Dusting GJ, Stubbs S, Arunothayaraj S, Han XL, Collas P, Morrison WA, Dilley RJ. Differentiation of human adipose-derived stem cells into beating cardiomyocytes. J Cell Mol Med 2010;14:878–889.
16. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, Pell CL, Johnstone BH, Considine RV, March KL. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004;109:1292–1298.
17. Caplan AI. Why are MSCs therapeutic? New data: New insight. J Pathol 2009;217:318–324.
18. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The ADVANCE Trial. J Am Coll Cardiol 2004;44:14–19.
19. Kissel CK, Lehmann R, Assmus B, Aicher A, Honold J, Fischer-Rasokat U, Heeschen C, Spyridopoulos I, Dimmeler S, Zeiher AM. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 2007;49:2341–2349.
20. Dimmeler S, Tjwa M. Better regenerative output after cellular input: Healing hearts by combining basic fibroblast factor and cell-based therapy. J Am Coll Cardiol 2008;52:1866–1868.
21. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Walter DH, Martin H, Zeiher AM, Dimmeler S. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004;109:1615–1622.
22. Premaratne GU, Ma LP, Fujita M, Lin X, Bollano E, Fu M. Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: Anti-inflammatory role. J Cardiothorac Surg 2011;6:43
23. Alexander RW. Understanding adipose-derived stromal vascular fraction (AD-SVF) cell biology and use on the basis of cellular, chemical, structural and paracrine components: A concise review. J Prolotherapy 2012;4:e855–e869.